The Center for Teaching & Learning welcomes Dr. Tino Unlap.

Tino UnlapTino Unlap, PhD (Biotechnology Program, Clinical & Diagnostic Sciences Dept., School of Health Professions) joined the Center for Teaching & Learning on August 25 in a part-time role. Dr. Unlap will be working to expand faculty enrichment opportunities. 

Dr. Unlap is a geneticist/biochemist with considerable experience teaching STEM undergraduate and graduate students.  He has received multiple teaching and mentoring awards, the most recent being a recipient of the President's Award for Excellence in Teaching.

Faculty News

UAB Cancer Center scientists present research at ASCO national meeting
UAB Cancer Center scientists present research at ASCO national meeting
Pioneering cancer research at UAB will be presented at the American Society of Clinical Oncology meeting.

cancer center ext 2013 9aA team of physician-scientists and researchers from the UAB Comprehensive Cancer Center will present some of the latest advances in cancer research to more than 25,000 oncology professionals during the 51st annual meeting of the American Society of Clinical Oncologyin Chicago May 29-June 2, 2015. 

UAB Cancer Center investigators are authors on more than 50 abstracts accepted by ASCO for the annual meeting. More than 25 abstracts include UAB researchers as a lead author. One of UAB’s highlighted presentations at this year’s meeting will be an observational study that indicates a more rapid decline in Medicare costs and patient resource utilization during implementation of a lay navigation program. Other topics range from examining patient navigation as a model to increase minority participation in cancer clinical trials, to using combination therapies with PARP inhibitors in treating HER2 positive-breast cancer, to investigating distress in older adult cancer patients approaching end of life.

Detailed information on all UAB abstracts is online at abstract.asco.org; search University of Alabama at Birmingham.

Boppana receives inaugural award for cytomegalovirus research
Boppana receives inaugural award for cytomegalovirus research
Suresh Boppana, M.D., received the award at the fifth annual International Congenital CMV Conference in Brisbane, Australia.

boppanaSuresh Boppana, M.D., professor of pediatric infectious diseases in the University of Alabama at Birmingham School of Medicine, is the recipient of the inaugural Congenital CMV (Cytomegalovirus) Award presented at the fifth annual International Congenital CMV Conference in Brisbane, Australia.

Boppana received the award at the April event, which gathered the world’s leading experts on CMV, a leading infectious cause of abnormalities including cerebral palsy and deafness in newborn babies. Boppana also presented the inaugural address at the conference: “Global Burden of Congenital CMV.”

UAB faculty members David Kimberlin, M.D., and Karen Fowler, Dr.P.H., also gave invited lectures at the conference.

Yang receives AACR career development award
Yang receives AACR career development award
UAB researcher awarded first joint AACR- TNBC Foundation Career Development Award focused specifically on triple negative breast cancer.

YungFrom left: Christine Wilson, Trustee for the Triple Negative Breast Cancer Foundation, Yang and Carlos L. Arteaga, immediate past president of the AACR. Photo by ACR/Todd Buchanan 2015Shih-Hsin (Eddy) Yang, M.D., Ph.D., associate professor at the University of Alabama at Birmingham Department of Radiation Oncology, has been awarded the 2015 American Association for Cancer Research-Triple Negative Breast Cancer Foundation Career Development Award for Clinical/Translational Research.

This award for $250,000 over three years represents a joint effort to encourage and support junior faculty to conduct triple negative breast cancer (TNBC) research and establish a successful career path in the field. This is the first year this grant has been awarded.

Yang, a scientist in the experimental therapeutics program at the UAB Comprehensive Cancer Center will study how EGFR, a protein coding gene, acts to regulate DNA repair pathways and how the barrier of this pathway induces tumor susceptibility to PARP inhibitors, a type of medication used in cancer treatment.

This research is compatible with an ongoing UAB pilot clinical trial, headed by Andres Forero, M.D., professor of hematology/oncology and senior scientist at the UAB Cancer Center, using the two therapies to treat patients with metastatic and recurrent TNBC. Yang will study the effects of this combination treatment using cancer tissue samples from before and after the therapy.

“We hope the combination will be effective for patients with TNBC, and with better understanding of how these pathways interact, we can potentially find out what it is about a patient’s particular cancer that makes it sensitive to this combination treatment,” said Yang.

Announcements

Video Reports